Skip to main content
SpringerLink
Log in

Etidronic acid and its calcium-comprising complexes in the treatment of experimental osteoporosis in estrogen-deficient rats

  • Science in CEE countries
  • Published:
Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen Aims and scope

Abstract

Aim

The aim of this study was to investigate the composition, stability, and biological activity of the complexes formed in solution upon interaction of calcium (Ca) ions with etidronic acid (EA), and to compare their effects on bone mineral density (BMD) in estrogen-deficient rats with osteoporosis.

Materials and methods

The study was conducted on 40 female Wistar rats. Osteoporosis was modeled by bilateral oophorectomy and therapy was started 4 months after surgery. Four groups were under study: the first group did not receive any osteoporotic treatment, only supplementation of Ca/vitamin D (D) in their diet. The second group received a single parenteral dose of EA with Ca/D supplementation. The third group received a Ca complex of EA (Ca-EA) without additional use of Ca/D. The fourth group received Ca-EA with Ca/D. Bone parameters (BMD and bone mineral content [BMC] in spine and total body) were measured by X‑ray densitometry using Prodigy (GE Medical systems, Model 8743, 2005; USA; program “Experimental animals”) thrice (before treatment, after 1 and 3 months of follow-up).

Results

Therapy with EA and Ca/D showed significant differences in total body BMD (tbBMD) only after 3 months. We established reliable changes in spine BMD (sBMD) and tbBMD after 1 and 3 months of treatment in group 3 rats: administration of Ca-EA with Ca/D had positive effects on sBMD at 1 and 3 months, and on tbBMD after 3 months. We did not establish any significant changes between sBMD and tbBMD after 1 and 3 months of therapy dependent on additional Ca/D supplementation (groups 3 and 4).

Conclusion

We showed a positive effect of the studied Ca-EA complexes on the BMD and BMC indices, with or without additional supplementation of Ca/D. More explicit dynamics of indices were observed in the group of animals treated with Ca-EA without additional Ca/D after 1 and 3 months of follow-up.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J‑Y, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO), Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57. https://doi.org/10.1007/s00198-012-2074-y

    Article  CAS  PubMed  Google Scholar 

  2. Camacho PM, Peak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016—Executive Summary. Endocr Pract 22(9):1111–1118. https://doi.org/10.4158/EP161435.ESGL

    Article  PubMed  Google Scholar 

  3. Povoroznyuk VV, Grygorieva NV, Orlyk TV et al (2014) Osteoporosis in the practice of internist doctor. Express, Kyiv (Russian)

    Google Scholar 

  4. Chan CK, Mason A, Cooper C, Dennison E (2016) Novel advances in the treatment of osteoporosis. Br Med Bull 119(1):129–142. https://doi.org/10.1093/bmb/ldw033

    Article  PubMed  PubMed Central  Google Scholar 

  5. Moore SN, Tanner SB, Schoenecker JG (2015) Bisphosphonates: from softening water to treating PXE. Cell Cycle 14(9):1354–1355. https://doi.org/10.1080/15384101.2015.1024585

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49(1):2–19. https://doi.org/10.1016/j.bone.2011.04.022

    Article  CAS  PubMed  Google Scholar 

  7. Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG (2011) The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49(1):20–33. https://doi.org/10.1016/j.bone.2011.03.774

    Article  CAS  PubMed  Google Scholar 

  8. Zhou J, Ma X, Wang T, Zhai S (2016) Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int 27(11):3289–3300. https://doi.org/10.1007/s00198-016-3654-z

    Article  CAS  PubMed  Google Scholar 

  9. Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM (2016) Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network mEA-analysis. Osteoporos Int 27(6):1989–1998. https://doi.org/10.1007/s00198-015-3476-4

    Article  CAS  PubMed  Google Scholar 

  10. Tartari T, Guimarães BM, Amoras LS, Duarte MA, e Souza SPA, Bramante CM (2015) Etidronate causes minimal changes in the ability of sodium hypochlorite to dissolve organic matter. Int Endod J 48(4):399–404. https://doi.org/10.1111/iej.12329

    Article  CAS  PubMed  Google Scholar 

  11. Council of Europe (1986) European convention for the protection of vertebrate animals used for experimental and other scientific purpose: Council of Europe 18.03.1986. Council of Europe, Strasbourg

    Google Scholar 

  12. Povoroznyuk VV, Deduh NV, Grygorieva NV, Gopkalova IV (2012) Experimental osteoporosis. Express, Kyiv (Russian)

    Google Scholar 

  13. Afonin EG, Aleksandrov GG, Ilyinsky AL (2000) Diprotonated 1‑hydroxyethane-1,1-diphosphonate of calcium. Russ J Inorg Chem 45(6):961–966

    CAS  Google Scholar 

  14. Gómez-Alcántara MM, Cabeza A, Martínez-Lara M, Aranda MA, Suau R, Bhuvanesh N, Clearfield A (2004) Synthesis and characterization of a new bisphosphonic acid and several mEAl hybrids derivatives. Inorg Chem 43(17):5283–5293

    Article  PubMed  Google Scholar 

  15. De Colli M, Tortorella P, Marconi GD, Agamennone M, Campestre C, Tauro M, Cataldi A, Zara S (2016) In vitro comparison of new bisphosphonic acids and zoledronate effects on human gingival fibroblasts viability, inflammation and matrix turnover. Clin Oral Investig 20(8):2013–2021

    Article  PubMed  Google Scholar 

  16. Ferrer-Casal M, Li C, Galizzi M, Stortz CA, Szajnman SH, Docampo R, Moreno SNJ, Rodriguez JB (2014) New insights into molecular recognition of 1,1-bisphosphonic acids by farnesyl diphosphate synthase. Bioorg Med Chem 22(1):398–405

    Article  CAS  PubMed  Google Scholar 

  17. Komisarenko SV, Sharykina NI, Lozynskyi MO, Lozynskyi MO, Karlova NP, Kudriavtseva IH, Kuzmenko IY, Borysevych AM, Yezerska LY (2001) Patent number UA 40714. Published 15.08.2001. Antitumor agent (mebiphon) Russian

Download references

Acknowledgements

We are grateful for the collaboration of the group of scientists of D. F. Chebotarev Institute of Gerontology of NAMS Ukraine (Kyiv, Ukraine) who performed bilateral oophorectomy and DXA measurement.

Author information

Authors and Affiliations

  1. State Institution D. F. Chebotarev Institute of Gerontology, Ukrainian National Academy of Sciences, Kyiv, Ukraine

    V. V. Povoroznyuk & N. V. Grygorieva

  2. V. I. Vernadsky Institute of General and Inorganic Chemistry, Ukrainian National Academy of Sciences, Kiev, Ukraine

    V. I. Pekhnyo, O. M. Kozachkova & N. V. Tsaryk

  3. St. Vincent Hospital Vienna, Academic Teaching Hospital, Medical University of Vienna, Vienna, Austria

    H. Resch

Authors
  1. V. V. Povoroznyuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. V. Grygorieva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. I. Pekhnyo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Resch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. M. Kozachkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. V. Tsaryk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. V. Grygorieva.

Ethics declarations

Conflict of interest

V.V. Povoroznyuk, N.V. Grygorieva, V.I. Pekhnyo, H. Resch, O.M. Kozachkova, and N.V. Tsaryk declare that they have no competing interests.

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Povoroznyuk, V.V., Grygorieva, N.V., Pekhnyo, V.I. et al. Etidronic acid and its calcium-comprising complexes in the treatment of experimental osteoporosis in estrogen-deficient rats. J. Miner. Stoffwechs. Muskuloskelet. Erkrank. 25, 7–12 (2018). https://doi.org/10.1007/s41970-017-0018-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s41970-017-0018-x

Keywords

Search

Navigation